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INTRODUCTION 
The relationship between Helicobacter pylori and gastric 
carcinoma is well documented. Therefore, Helicobacter pylori has been 
designated as a definite carcinogen by the IARC (International Agency 
for Research on Cancer) which is a branch of the WHO (World Health 
Organization).  
Epidemiological studies show that the H.pylori infected persons 
have a greater risk of developing gastric adenocarcinoma.(1) In 2001, an 
analysis of 12 studies involving gastric cancinoma and H.pylori estimated 
that there was a six times increased risk in the development of  
adenocarcinoma in the non-cardia regions of the stomach for persons 
infected with H.pylori than those who were not infected.(2) 
The intestinal type of gastric carcinoma is thought to occur due to 
environmental causes such as H.pylori infection. However, the diffuse 
gastric cancer is thought to occur due to a primary genetic cause. 
Allocating values to the genetic and the environmental contributions in 
the developing of the intestinal type of gastric carcinoma is difficult since 
familial clustering is also seen in H.pylori. 
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10% of the total gastric cancer cases demonstrate familial 
clustering.(3) Therefore, family history of gastric malignancy can be 
considered an independent risk factor by itself for the development of 
gastric carcinoma in spite of adequate H.pylori control.  
Genetic factors that play a role in the immune response of a person 
to H.pylori infection may be responsible for the familial clustering of 
gastric carcinoma patients (intestinal type).  
The development of atrophic gastritis has been associated to a 
strong immune response involving the Th1 cells. This led to the 
postulation of the theory that the genes responsible for disease 
susceptibility in both gastric carcinoma as well as atrophic gastritis may 
also participate in the immune response to Helicobacter pylori infection.  
Uemura et al conducted a study in a set of patients with early 
gastric cancer who underwent EMR.(4) These patients were distributed 
into two groups. In the group which received anti-H.pylori treatment 
following EMR, none developed secondary gastric carcinoma. But in the 
group that did not undergo H.pylori eradication, 9% of them went on to 
later develop secondary gastric carcinoma. This study demonstrated that 
treating Helicobacter pylori infection may prevent development of 
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secondary gastric carcinoma and therefore should be done in persons who 
undergo EMR for early gastric carcinoma.  
Due to the hereditary risk for gastric carcinoma in first degree 
relatives of patients with gastric cancer, eradication of H.pylori may help 
avoid one of the factors that potentiate the risk of developing gastric 
carcinoma. 
Eradication of H.pylori infection can result in many physiologic 
effects that may decrease the risk of developing gastric carcinoma. The 
effects are a reduced cell turnover, increased gastric acid secretory 
capacity, eliminating DNA damage by reducing the reactive oxygen 
species and restoring ascorbic acid secretion into the gastric secretions.  
But concrete evidence proving that eradication of Helicobacter 
pylori has a protective effect from the development of gastric carcinoma 
in the form of well-designed clinical studies remains less. 
  
 
4 
 
 
 
 
 
REVIEW OF 
LITERATURE   
 
4 
 
REVIEW OF LITERATURE 
Gastric carcinoma is the second leading cause of mortality due to 
cancer globally. There is a large geographical variation in incidence of 
gastric carcinoma with the lowest incidence being seen in South Asia, 
North America, North Africa and Australia. 
EPIDEMIOLOGY 
In India, gastric carcinoma ranks fifth among cancer seen in males 
and seventh among cancer seen in females. The age-adjusted rate (AAR) 
of gastric cancer among urban registries in India is 3.0–13.2 compared to 
the worldwide AAR (4.1–95.5). (10) 
The worldwide decline in the incidence of gastric cancer has been 
attributed to an improvement in food hygiene, sanitation and techniques 
of food preservation. But, this decline in incidence is not seen in certain 
regions of India.(11) This regional variation in incidence and presentation 
is reflected in the fact that gastric cancer in South Indian males is found 
to be more common and occurs almost a decade before their North Indian 
counterparts.(12) 
In India, the highest incidence of gastric carcinoma is seen in 
Mizoram.(13) The AAR rate of stomach cancer in India as per the National 
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Cancer Registry had the highest value in Chennai of 11.1 per 100,000 for  
males and 5.4 in females. 
Differences in some dietary pattern and use of tobacco and alcohol 
are considered as potential risk factors. In a case–control study from 
Trivandrum, a high intake of rice and chilli along with consumption of 
high-temperature food were identified as independent risk factors for 
developing gastric malignancy.(14) In a study conducted at Hyderabad, 
comparing 94 gastric cancer patients and 100 normal matched controls, 
smoking (P<0.01) and alcohol (P<0.05) were found to be significantly 
associated with gastric carcinoma.(15) 
High prevalence of gastric carcinoma in Mizoram has been 
attributed to dietary and possibly some unknown genetic differences. In a 
case–control study from Mizoram, the risk of stomach cancer was much 
higher in current smokers from among the cases.(16) In another study from 
Chennai, alcohol consumption and eating pickled food were identified as 
independent risk factors for gastric carcinoma.(17) 
ETIOPATHOGENESIS 
The most common location of the tumor was in the body of 
stomach (40.7%) followed by the pylorus (35.5%). Gastric carcinoma can 
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be classified as either intestinal or diffuse as suggested  by Lauren et al. 
based on histological findings.(18) Gastric carcinoma is also classified 
according to the anatomic site as proximal (cardia, fundus, and GE 
junction) or distal (pylorus). Incidence of proximal gastric cancers is 
increasing in the developed world along with an increase in esophageal 
cancers suggesting that both these entities might have similar risk factors 
and pathologies.  
H.pylori is thought to cause distal gastric cancers and that the 
overall decline in gastric cancers and more specifically distal cancers 
worldwide is thought to be due to the reduction or eradication of H.pylori 
infection due to improved sanitation.(19) Therefore, it is thought that 
countries that have a very high prevalence of h.pylori should have the 
most incidence of gastric carcinoma. However this isn’t true, as Asia and 
Africa have high incidences of Helicobacter pylori infection but a low 
incidence of gastric carcinoma. This paradox suggests that H.pylori by 
itself cannot cause gastric cancer and a combination of other factors is 
needed for gastric carcinoma to develop.(20) 
Various definite factors that place a person at risk for developing  
gastric carcinoma are H.pylori infection, chronic atrophic gastritis, 
intestinal metaplasia, dysplasia, adenomatous gastric polyps, cigarette 
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smoking, H/O gastric surgery, genetic factors, family H/O gastric cancer 
(first-degree relatives), FAP with fundic gland polyps, HNPCC, Peutz-
Jeghers syndrome and juvenile polyposis. 
MICROBIOLOGY 
Helicobacter pylori is a gram-negative microaerophilic bacterium 
that has been identified as the primary aetiologic agent for gastric 
carcinoma. H.pylori has been designated as a definite carcinogen by the 
International Agency for Research on Cancer (IARC). 
Helicobacter pylori are unique bacteria that are suited to live in the 
acidic environment present in the human stomach. The spiral shape along 
with the multiple unipolar flagella of the organism allows it to move in a 
free manner through the gastric mucous layer, where it may stay 
protected from low gastric pH.(21) They produce huge amounts of urease 
which is an enzyme that hydrolyzes urea to alkaline ammonia and CO2.  
EPIDEMIOLOGY OF H.PYLORI 
In developing countries, most children are infected by 10 years and 
spontaneous elimination and subsequent reinfection are common in 
childhood. This infection may persist into adulthood and therefore 
prevalence of Helicobacter pylori in the developing countries reaches 
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>80%. Serological evidence of H.pylori is almost nil in children below 10 
years, but increases to 10% in adults (18-30 years) and further to 50% in 
people older than 60 years. (22) 
Twins who grow up together in the same environment have a 
greater concordance of Helicobacter pylori status than those twins who 
grow up separately. 
Person to person bacterial transmission from feco-oral, oro-oral or 
gastro-oral means is the most likely explanation for infection. 
PATHOGENESIS 
Helicobacter pylori shows strict affinity for gastric mucosa and 
intestinal epithelium with gastric metaplasia. It does not colonize gastric 
epithelium with intestinal metaplastic change, as the production of 
antimicrobial factors select against colonization. Helicobacter pylori very 
rarely colonize the deeper parts of the gastric glandular mucosa since O-
glycans present there impair its growth.(23) H.pylori reduces the secretory 
leukocyte protease inhibitor (antibacterial molecule) which could prevent 
the infection from persistence. (24) 
Another factor that affects colonization is the receptor expression 
on the host cells which allow H. pylori to bind to Lewis (Le) antigens 
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expressed by host cells.(25) Specific bacterial gene products, mainly BabA, 
act as a bacterial ligand for the Leb receptor.(26) Few studies have 
suggested that the babA2 genotype is more commonly associated with 
duodenal ulcer and gastric carcinoma.(27) 
Helicobacter pylori also binds to the molecular complex of 
invariant chain and class II HLAs expressed on the gastric epithelial cell 
surface.(28) The Class II major histocompatibility complex  molecules 
were the first epithelial cell receptors for Helicobacter pylori that were 
demonstrated to directly affect signaling in host cells. Apoptosis of the 
host cells is induced when urease binds to the epithelial cells. (29) 
Recently, the gastric trefoil protein TFF1 has been shown to serve as a 
receptor for Helicobacter pylori. (30)  
The Toll-like receptors are a family of PAMPS (pathogen-
associated molecular receptors) that may bind bacterial products and 
enhance bacterial binding and cell signaling. (31) 
After H. pylori migrates to the gastric epithelium, it attaches to host 
cells and may damage them so as to obtain nutrients from the subsequent 
inflammatory exudate or transudate. The main interaction between the 
bacteria and gastric epithelium involves a segment of bacterial DNA 
called the cag pathogenicity island (cag PAI). The genes within the cag 
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PAI encode proteins that may provide a type IV secretion apparatus (i.e., 
cagE) that permits bacterial macromolecules to translocate into the host 
cell (i.e., cagA).(32) H.pylori bearing the cag PAI are associated with 
increased IL-8 expression as also inflammation in the gastric mucosal 
biopsy specimens and increased IL-8 expression and apoptosis in vitro.(33) 
Superoxide (O2−) and nitric oxide (NO), produced by infiltrating 
neutrophils, in a reaction form peroxynitrite (ONOO−) which is a potent 
reducing agent as well as an oxidant. Urea is hydrolysed by urease to give 
carbon dioxide that reacts with peroxynitrate and forms ONO-OCO2 
thereby neutralizing peroxynitrate’s bactericidal activity. Urease is said to 
enhance the nitration potential of ONOO− thus favoring mutagenesis of 
host cell DNA. 
GIT antibodies are usually IgA, which are adapted for protection of 
the mucosa and confer protective immunity without activation of the 
complement cascade. During Helicobacter pylori infection, IgA 
producing cells increase in number. IgM and IgG may also be detected, 
along with activated complement. 
H.pylori infection may be present throughout the life of the host 
unless antibiotics intervene in its course. Many bacterial factors such as 
catalase and urease, antagonize innate responses of the host cell.  
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NATURAL HISTORY OF H.PYLORI 
The natural history of chronic H. pylori infection includes the 
following phenotypes (34): (1) superficial gastritis (2) duodenal ulcer and 
(3) gastric ulcer/gastric cancer. H. pylori–induced duodenal ulcer patients 
have an increased gastric acid output and a decreased risk for developing 
gastric carcinoma. (35) 
HELICOBACTER PYLORI AND GASTRIC CARCINOMA 
Patients with H. pylori associated gastric ulcer have a low gastric 
acid output, and their ulcers are usually associated with premalignant 
changes such as atrophic gastritis and intestinal metaplasia. Helicobacter 
pylori infected patients can develop atrophic gastritis at a rate of 1 to 3% 
every year.(36) Helicobacter pylori is associated with both the intestinal 
and diffuse-types of adenocarcinomas. 
The higher risk of developing gastric adenocarcinoma secondary to 
H. pylori infection depends on many factors such as the strain of bacteria, 
duration of infection, host genetic factors along with the absence/presence 
of other factors such as poor diet, smoking, etc.  
In a Japanese study that included 1526 persons with PUD, gastric 
hyperplasia and non-ulcer dyspepsia, only Helicobacter pylori infected 
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persons developed gastric adenocarcinoma on follow-up (P < 0.001).(37) 
In the West, this association between H. pylori and gastric carcinoma 
seems to be restricted to tumors not involving the cardia.(38) 
A combination of a genetically permissive host, a virulent bacterial 
strain and a favorable environment in the stomach are required for gastric 
cancer to develop. However, the most important factor appears to be the 
inducing of chronic inflammation by H. pylori. Many carcinogens have 
been implicated including oxygen free radicals (that can damage DNA), 
increased CD4+ T cells as well as myeloid cells and also increased 
production of proinflammatory cytokines. These lead to increased cell 
turnover, decreased apoptosis and increase the potential for incomplete or 
faulty DNA repair.(39) Thus, current evidence indicates that the host 
immune response is the most significant cofactor that can induce 
development of H.pylori related disease. 
Prolonged inflammation is required for the disease to progress via 
atrophy to gastric carcinoma. Studying the mechanisms of H.pylori 
related disease is difficult in humans and much of our understanding of 
the immune response to Helicobacter organisms is from the work done 
on mouse models. 
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Observations in mouse models laid the path for the conduction of 
studies in humans which were done in Latin America and Africa. These 
studies confirmed that those areas with low gastric carcinoma incidence 
had a higher Th2 when compared with Th1 immune responses to 
Helicobacter pylori.(40) In areas where intestinal helminths were present in 
more than 50% of the population and serum IgE levels were elevated, an 
increased Th2-type response was found.  
Diverse genetic variations are seen between different strains of H. 
pylori due to base-pair substitutions within its genome, deletions, 
insertions and point mutations. Inspite of this genetic diversity, many 
genes have been identified as risk factors for gastric cancer, such as the 
cag PAI, the babA2 gene along with the vacA gene. 
The H. pylori genome contains 1.65 million base pairs and codes 
for nearly 1500 genes. Biological roles have been identified for two-
thirds of these genes while the roles played by rest of the  one-third of the 
genome is unknown. (41) 
Motility of H.pylori towards the gastric epithelial cells is ensured 
by many factors, including its spiraling movement (FlaA and FlaB 
proteins), that help the organism to move through the thick gastric mucus 
and decrease its viscosity permitting penetration of bacteria.(42)  
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H. pylori also expresses many genes that help to buffer gastric acid 
so as to maintain a relatively neutral pH. One of these is the urease gene 
cluster which is made up of 7 genes, of which UreA/UreB complex 
(urease enzyme) codes for nearly ten percent of H. pylori protein and is 
necessary for the survival of the bacteria. 
Most of H. pylori organisms are found on the gastric mucosal cell 
surface. Some H. pylori can be seen within the cell, mainly in 
premalignant and malignant lesions.(43) Bacterial adherence to the gastric 
epithelial layer is helped by a family of 32 related outer-membrane 
proteins (Hop proteins) that include adhesins. BabA is an adhesin 
encoded by the strain-specific gene babA2. BabA binds to the fucosylated 
Lewis B blood group antigen on the gastric epithelial cells to form a 
scaffold apparatus that permits the bacterial proteins to enter host 
epithelial cells. Helicobacter pylori strains possessing the babA2 gene 
show tight adherence to epithelial cells and promote an aggressive 
phenotype that is associated with a higher incidence of gastric 
adenocarcinoma.(44) 
The cag PAI is about 40 kb and contains 31 genes. CagA, the 
terminal gene of this island, is used as a marker for the entire cag locus. 
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The cag-positive (cagA+) strains are associated with greater degrees of 
atrophic changes, more severe inflammation, and a higher risk for 
progression to gastric adenocarcinoma.(45) 
CagA could directly promote transformation, growth and 
migration. Other genes within the PAI may be important for development 
of disease as they may be necessary in vitro epithelial cell cytokine 
release, but they dont appear to have sa great an effect on immune cell 
cytokine activation as  cagA. (46) This can explain the attenuated 
inflammatory response and the decreased risk of cancer seen with cagA− 
strains in vivo.(47) 
All the strains of H. pylori carry the vacA gene that codes for a 
pore-forming vacuolating toxin. However, the expression of vacA can 
differ depending on allelic variation. Nearly 50% of H. pylori strains 
express the vacA protein, which inhibits T cell activation in vitro.(48) 
Though cagA and vacA map to different loci within the Helicobacter 
pylori genome, the vacA protein is commonly expressed in cagA+ strains. 
“Virulent strains” (cagA+, cagE+, and VacA+ s1m1) seem to induce the 
proinflammatory mediators much more than the “nonvirulent strains” 
(cagA−, cagE−, and VacA−). This can explain the high association of 
cagA+ strains with gastric carcinoma. 
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INVESTIGATIONS FOR H.PYLORI 
The American College of Gastroenterology (ACG) guidelines 
recommend tests for H. pylori infection only if the physician is ready to 
treat all patients who test positive.(49) Asymptomatic persons need not be 
treated except persons with a family h/o gastric carcinoma. 
Indications for Testing and Treatment of Helicobacter pylori 
Infection 
Supported by evidence 
  Active peptic ulcer disease (gastric or duodenal ulcer) 
  Confirmed h/o peptic ulcer (not previously treated for H. pylori) 
  Gastric MALT lymphoma (low grade) 
  Following endoscopic resection of early gastric cancer 
  Uninvestigated dyspepsia (if H. pylori population prevalence high) 
 Controversial 
  Functional dyspepsia 
  GERD 
  Patients on NSAIDs, especially when initiating NSAID treatment 
  Unexplained IDA/ITP 
  Populations with increased risk of gastric carcinoma  
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Diagnosis of Helicobacter pylori may be done by endoscopic as 
well as non-endoscopic methods. Some techniques directly detect 
H.pylori such as histologic demonstration of H.pylori, detection of 
bacterial antigen in the stool & culture of the organism. Other methods 
detect Helicobacter pylori indirectly as in urease tests and evaluation of 
an antibody response to mark the presence of Helicobacter pylori by 
serology.(50) 
Diagnostic Tests for Helicobacter pylori 
During an endoscopic procedure, 3 methods can be used to identify 
H.pylori.They are the urease test of biopsy specimen, histopathological 
examination and culture.  Urease test of biopsy specimen has been 
proposed as the initial test of choice since the method is quick, relatively 
inexpensive, generally accurate and easy to perform. The gastric tissue 
specimen is tested for activity of urease by putting many bits of tissue in a 
medium containing pH reagent and urea. Urease produced by H.pylori 
hydrolyzes urea and liberates ammonia, which produces an alkaline pH 
and this results in a change in colour of the test medium. The test results 
can be read in a few minutes to hours. This test is less costly than 
histological examination. Therefore, a cost-cutting measure is to delay 
sending tissue for histological examination till urease test results are 
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available. Urease tests are 95% to 100% specific with false-positive tests 
being not very common.(51) Accuracy of the urease test can be affected by 
the presence of blood in the stomach (52) and also recent/current use of 
drugs such as bismuth-containing compounds, antibiotics or PPIs. (53) 
Urease test negativity therefore cannot exclude H. pylori infection in an 
individual taking the above medications. Testing biopsy tissues from 
various regions of the stomach, stopping the offending drug for a few 
weeks and delayed UGI scopy can improve the sensitivity of the test. 
Histopathological examination of the gastric mucosa isn’t 
necessary for the diagnosis of H.pylori. However, this test may provide 
information about the activity of Helicobacter pylori and mucosal 
inflammation severity. Histological examination can also detect the 
presence of metaplasia, dysplasia, and neoplasia. Biopsy of “clinically 
suspicious” areas, multiple biopsies, taking samples from both the lesser 
and greater curvatures of gastric antrum as well as the body should be 
done mainly when searching for atrophic gastritis and/or intestinal 
metaplasia.  Histopathologic exam is the gold standard for confirmation 
of Helicobacter pylori infection. This test is 95% sensitive and 98% 
specific.(54) Detecting organisms is better when tissue is processed with 
special stains like Silver stain, Giemsa stain or Genta stain or specific 
immune stains.(55) 
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Helicobacter pylori culture is difficult, since it is very fastidious, 
grows slowly and requires use of specialized media and a controlled 
growth environment. When culturing for Helicobacter pylori, the biopsy 
forceps should not be contaminated with formalin prior to obtaining the 
tissue specimen. The tissue specimen should be kept in a container that 
contains a few drops of saline for preservation of the tissue while being 
transported to the microbiology laboratory. Culture is advised only for 
persons with refractory disease where identifying sensitivity to antibiotics 
may help in guiding subsequent treatment. 
Nonendoscopic tests are more commonly used in the diagnosis of 
Helicobacter pylori with serology being the most popular test used. 
ELISA detects the presence of IgG antibodies to many bacterial antigens 
seen in the serum. Testing for IgA and IgM class antibodies is unreliable 
and therefore cannot be recommended. Though serology is cheaper, not 
invasive and ideal in a primary care setting, its accuracy depends on 
prevalence of  Helicobacter pylori in the population that is being tested. 
Serology is highly sensitive (90% - 100%) but the specificity varies (76% 
to 96%), mainly in areas where prevalence of Helicobacter pylori is low. 
In regions where the prevalence of H.pylori is low, the NPV of serology 
is high while the PPV is low.(56) Therefore, serology tests that are positive 
should always be confirmed with any other method like  a stool antigen 
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or urea breath test prior to the start of therapy. Otherwise, it is better to 
initially go for a test that can detect active Helicobacter pylori infection. 
After treatment, if a positive serological test becomes negative, it 
indicates a cure. Even after successful eradication of H.pylori, the 
serology may remain positive for months to years.(57) Because of this 
“serologic scar”, serology can’t be used to confirm eradication of 
H.pylori after treatment. 
The urea breath test detects an active Helicobacter pylori infection 
and is therefore can be used for making the primary diagnosis, to confirm 
the accuracy of the serological test as well as the documenting of 
successful treatment.Urea breath test depends on hydrolysis of orally 
administered carbon isotope tagged urea (13C or 14C) by Helicobacter 
pylori. This gives rise to ammonia and tagged CO2 that is detected in 
breath samples. Since 13C is a non-radioactive isotope, it is better for use 
in pregnant women and children. The radiation dose exposure with the 
14C test is 1 microCi.(58) UBT has more than 95% specificity  and so, 
false-positive results are not very common. The sensitivity of UBT is 
88% -95% with false-negative results seen in those on antisecretory drugs 
mentioned earlier. Therefore for improving the accuracy of the test, 
antibiotics shouldn’t be given 4 weeks and PPIs for at least 1 week prior 
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to breath testing.Urea breath test is inaccurate in persons with previous 
H/O gastric resective surgery. 
A stool immunoassay helps detect the bacterial antigens in H.pylori 
infected patients. This method can be used to diagnose active 
Helicobacter pylori infection and also to confirm eradication of H.pylori 
following treatment. The stool test is 94% sensitive and 97% specific and 
these are comparable with that of the urea breath test. Here too, the 
sensitivity of stool testing sensitivity can be affected by antibiotics, PPI 
etc., that may reduce bacterial load. Therefore, precautions similar to 
those for urea breath test need to be followed while doing the stool 
tests.(59) 
Though PCR is  very sensitive for detecting H. pylori in gastric 
tissue biopsies, it isn’t practically useful for routine clinical purposes. 
This test is only used for research purposes for identification of the 
bacteria when culture may be difficult.(60) 
The current recommendations for H.pylori testing are as follows: 
The initial test preferred for the diagnosis of Helicobacter pylori is 
either UBT or a stool antigen assay as they help in the detection of active 
infection. Serological testing is useful only for exclusion of Helicobacter 
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pylori infection. Endoscopic biopsy can be done for patients who have an 
ulcer or MALT lymphoma and also in persons who require a follow-up 
OGD scopy for gastric ulcer follow-up. Urease testing on tissue biopsy 
specimens can be done in those not on anti-secretory medications and 
when histopathological examination is not necessary. 
Successful Helicobacter pylori eradication can be confirmed when 
clinically indicated with either a urea breath test or stool antigen test. 
However they shouldn’t be done earlier than 4-6 weeks following 
treatment completion as early testing may show false-negative results. 
Here too, antisecretory drugs should be stopped at least 1 week before 
testing so as to improve the accuracy. Serology isn’t useful for follow-up 
as it may remain positive in a lot of patients for a few months or 
sometimes even years after eradication of H.pylori. 
TREATMENT OF H.PYLORI 
A sequential regimen given for 10 days improved the rate of 
eradication in comparision with the standard PPI triple therapy (89% vs. 
77 %). The drugs given are a Proton Pump Inhibitor and Amoxicillin for 
the initial five days and then Proton Pump Inhibitor along with 
clarithromycin and tinidazole for the next five days. A pooled analysis of 
various studies confirmed that sequential therapy is better, more so in 
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macrolide-resistant strains.(61) Dual regimens with a solo antibiotic and a 
Proton Pump Inhibitor are not recommended as the rate of eradication is 
much lesser than the triple drug regimens.(62) 
Bismuth-based therapy, with a combination of a bismuth salt, 
metronidazole, tetracycline along with a PPI daily for 14 days was one of 
the first combinations used in the therapy of H. pylori. Though it is highly 
effective with >80% eradication, the large number of tablets and frequent 
minor side effects has a negative effect on tolerability and compliance. 
Therefore, this regimen is kept in reserve as either a second-line regimen 
or a retreatment regimen.(63) 
Initial treatment of H. pylori infection may fail in up to 25% of 
patients due to either drug resistance, poor compliance or due to patient 
factors such as younger age, previous antibiotic use, smoking, and 
presence of functional dyspepsia.(64) Another “rescue therapy” includes a 
PPI, levofloxacin , along with amoxicillin for 10 days is approximately 
80% effective. Another combination of PPI and amoxicillin, along with 
rifabutin for 10 days is reportedly effective in 85% patients.  
Initially treatment for Helicobacter pylori can be started with a 10- 
to 14-day course of PPI triple therapy (Proton pump inhibitor, 
clarithromycin and amoxicillin) but the 10 day sequential regimen can be 
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an alternative if resistance to clarithromycin is suspected. If infection 
continues to persist even after the above, retreatment with one of the 
other PPI triple regimens or a bismuth based regimen is given for 2 
weeks. Selecting a treatment regimen on the basis of antibiotic sensitivity 
is not recommended as a matter of routine. 
STUDIES ANALYSING ASSOCIATION OF HELICOBACTER 
PYLORI AND GASTRIC PREMALIGNANT CHANGES IN FIRST 
DEGREE RELATIVES OF PATIENTS WITH GASTRIC 
CARCINOMA 
In a study by Brenner H et al, they compared the prevalence of H. 
pylori in subjects with and without parental H/O gastric carcinoma to 
evaluate the role of Helicobacter pylori in familial aggregation of gastric 
carcinoma. Totally, 1351 males and females aged between 30 and 74 
years were included in the study. The prevalence of Helicobacter pylori 
was much higher (69%) among those with a parental H/O gastric 
carcinoma than among the others (44%). These results indicate that 
familial aggregation of gastric carcinoma can be explained partially by 
familial clustering of Helicobacter pylori infection. 
In another study by El-Omar EM et al, Helicobacter pylori 
infection, gastric secretory function, and histological examination of 
stomach were assessed in 100 first-degree relatives of gastric carcinoma 
patients and compared with controls that did not have family H/O gastric 
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carcinoma. Relatives of patients with gastric carcinoma had an increased 
prevalence of premalignant changes, but this was restricted to persons 
with Helicobacter pylori infection. Therefore, prophylactic H.pylori 
eradication should be offered to these persons.  
In a State of the Art Critique published in The American Journal of 
Gastroenterology in 2005 by Peter Malfertheiner et al, the conclusion was 
as follows: “Based on "in depth" evidence presented at this workshop, the 
majority of the scientific task force favored a search-and-treat strategy in 
first-degree relatives of gastric cancer patients and an overwhelming 
majority felt that a more general screen-and-treat strategy should be 
focused in the first instance in a population that has a high incidence of 
Helicobacter pylori associated diseases.” 
There is a lack of literature available on studies done in this aspect 
in India. Hence, this study was done to find the prevalence of 
Helicobacter pylori and assess its impact on gastric premalignant changes 
in first degree relatives of gastric carcinoma patients. 
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AIM OF THE STUDY 
 To assess the prevalence of gastric Helicobacter pylori infection in 
first degree relatives of gastric carcinoma patients and compare it 
with the same in the controls 
 To look for presence of premalignant histological changes in the 
stomach in the above persons 
 To look for any association between Helicobacter pylori and 
presence of premalignant changes in the study subjects 
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MATERIALS AND METHODS 
This case control study was carried out in the Department of 
Digestive Health and Diseases, Government Peripheral Hospital, Anna 
Nagar, Chennai from January 2012 to February 2013. 
Approval for the conduct of this study was obtained from the 
Ethical Committee at Kilpauk Medical College prior to starting the study. 
INCLUSION CRITERION 
• First degree relative of a gastric carcinoma patient 
EXCLUSION CRITERIA 
• Presence of peptic ulcer and /or GI bleeding on endoscopy 
• Previous H/O gastrectomy 
• Presence of any life-threatening condition 
• Consumption of PPIs/H2RAs/NSAIDs/Antibiotics 4 weeks prior to 
endoscopy 
• Persons who refused OGD scopy 
Patients attending the DDHD, GPH, Anna Nagar, Chennai who 
had gastric carcinoma were identified and their first degree relatives 
(siblings or children) listed out.  
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These persons were then informed about the study and written 
informed consent was obtained for including them in the study. 
From these listed persons, those who had the exclusion criteria 
were omitted and the rest were included in the study. 
This was compared with the control group that had no family H/O 
gastric carcinoma. These patients were people who reported to our out-
patient department for other symptoms. Written informed consent from 
them also was obtained prior to including them in the study. Those who 
came under the exclusion criteria were excluded from the study. 
After getting a detailed history regarding any complaints, drug 
intake, surgery and substance abuse, clinical examination of the patient 
was performed.  
Then, the subject was subjected to upper GI endoscopy. Those with 
any of the findings listed under the exclusion criteria were ruled out from 
the study. 
Finally a total of 100 persons were recruited for this study, 50 in 
the study group and 50 in the control group. 
Both the control and test groups were matched for both age as well 
as sex. 
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From every person in the study, multiple biopsies were taken from 
the stomach as per the Sydney system. A minimum of five tissue 
specimens were biopsied: two specimens were taken from the antrum 
within 2 to 3 cm from the pylorus, two from the body about 8 cm from 
the cardia (one each from the lesser and greater curvatures) and one 
specimen from the incisura. 
One tissue specimen was used for the rapid urease test, wherein a 
colour change from yellow to various shades of pink within an hour 
denoted the presence of Helicobacter pylori. 
The rest of the tissue specimens were then sent to the Department 
of Pathology, Kilpauk Medical College for histopathological 
examination. 
The same procedure was also repeated with the subjects in the 
control group. 
The results were then tabulated and analysed. 
Statistical analysis of the data was done using the software SPSS 
(version 17). 
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Helicotec-UT (Rapid urease test) 
Helicotec-UT is a slide test designed to detect Helicobacter pylori 
by the presence of its urease activity in gastric mucosal biopsy specimens. 
Helicobacter pylori produce large amounts of urease which hydrolyze 
urea into ammonium ion and bicarbonate. 
When the tissue specimen of a patient is immersed in the 
Helicotec-UT test gel and observed over a period of time, the elevated pH 
caused by the activity of urease is demonstrated by a colour change of the 
pH indicator in the test gel. 
The pre-test gel is yellow in colour. If the colour changes to pink 
after placing the tissue specimen in the gel, the test is positive for 
H.pylori. If the gel remains yellow in colour, then the test is negative for 
H.pylori. 
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RAPID UREASE TEST KIT USED IN THIS STUDY-  
HelicotecUT® PLUS 
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RESULTS AND STATISTICAL ANALYSIS 
A total of 100 persons were recruited for this study.  
50 persons who were first degree relatives of patients with gastric 
carcinoma formed the study group after applying the exclusion criteria. 
50 persons who presented to our department with other complaints 
were recruited for the study to act as controls after obtaining their 
consent. 
Statistical analysis was done using independent sampling T-test for 
analysis of age whereas the chi square test was used for the rest of the 
parameters using the SPSS software (Version 17). 
The levels of the P-value and its significance are as follows: 
1) P-value of 0.000 to 0.010 indicates that the data correlation is 
significant at the 1 % level (denoted by **) 
2) P-value of 0.010 to 0.050 indicates that the data correlation is 
significant at the 5 % level (denoted by *) 
3) P-value of 0.051 to 1.000 indicates that it is not statistically 
significant at the 5% level 
4) P-value = 0.000 indicates high statistical significance (denoted by 
<0.001 **) 
 
33 
 
Both the study group and control group were found to match for 
age by the T-test and for the gender by the chi-square test. 
Both the groups were matched for age (p=0.856). 
In the study group, there were 31 males and 19 females whereas 
there were 30 males and 20 females in the control group (p=0.838). 
There were a total of 45 alcoholics (24 in the study group and 21 in 
the control group). Association between alcohol and prevalence of 
Helicobacter pylori was statistically significant in both the study and 
control groups. 
There were a total of 49 smokers (26 in the study group and 23 in 
the control group). Association between smoking and prevalence of 
H.pylori was statistically significant in the control group but was not 
significant in the study group. 
There were a total of 37 tobacco chewers (20 in the study group 
and 17 in the control group). ). Association between tobacco chewing and 
prevalence of Helicobacter pylori was statistically significant in both the 
study and control groups. 
Significantly, none of the female subjects were either alcoholics or 
smokers. 
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In the control group, the rapid urease test was positive in 29 
persons (18 males and 11 females), whereas it was positive in 39 persons 
(25 males and 14 females) in the study group (p=0.032*). 
The prevalence of Helicobacter pylori among males was 81% in 
the study group whereas it was 60% in the control group. 
The prevalence of Helicobacter pylori among females was 74% in 
the study group whereas it was 55% in the control group. 
In the control group, histological examination revealed 
Helicobacter pylori in 25 persons (15 males and 10 females), whereas it 
was positive in 34 persons (22 males and 12 females) in the study group 
(p=   0.067). 
In the control group, 25 out of the 29 persons (86%) who showed a 
positive rapid urease test also showed the bacteria on histological 
examination. But 4 (14%) persons with a positive rapid urease test failed 
to demonstrate the histological presence of Helicobacter pylori (p=0.000). 
In the study group, , 34 out of the 39 persons (87%) who had a 
positive rapid urease test showed the bacteria on histological 
examination. But 5 (13%) persons with a positive rapid urease test failed 
to demonstrate the histological presence of Helicobacter pylori (p=0.000). 
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But in both the groups, all those persons who demonstrated 
Helicobacter pylori histologically were positive for the rapid urease test. 
Premalignant changes in the stomach were seen only in 4 persons- 
all of them in the study group only (p= 0.268). The only premalignant 
change seen in our study was atrophic gastritis. Intestinal metaplasia and 
dysplastic changes in the stomach were not seen in our study.  
The significant factor here was the occurrence of premalignant 
changes only in those persons who tested positive for Helicobacter pylori. 
AGE 
  Group  N  Mean 
Std. 
Deviation 
Std. Error 
Mean 
Age in 
years 
Control  50  36.14  11.148  1.577 
Study  50  35.74  10.795  1.527 
 
  t-test for Equality of Means 
 
t  df  Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower  Upper
Age in 
years  .182  98  .856  .40  2.195  -3.955  4.755 
  .182  97.898  .856  .40  2.195  -3.955  4.755 
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SEX 
 
 
 
Group  Total 
 
P 
value 
Control Study   
Sex  Male  Count  30  31  61   
 
 
 
 
 
0.838 
      % within Sex  49.2%  50.8%  100.0% 
      % within Group  60.0%  62.0%  61.0% 
   Female  Count  20  19  39 
      % within Sex  51.3%  48.7%  100.0% 
      % within Group  40.0%  38.0%  39.0% 
Total  Count  50  50  100 
   % within Sex  50.0%  50.0%  100.0% 
   % within Group  100.0%  100.0% 100.0%   
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RAPID UREASE TEST 
 
Group  Total   
Control  Study  P value
Rapid 
Urease 
Positive  Count  29  39  68 
 
      % within Rapid 
Urease  42.6%  57.4%  100.0% 
 
 
      % within 
Group  58.0%  78.0%  68.0% 
 
   Negative  Count  21  11  32   
      % within Rapid 
Urease  65.6%  34.4%  100.0% 
0.032* 
      % within 
Group  42.0%  22.0%  32.0% 
 
Total  Count  50  50  100   
   % within Rapid 
Urease  50.0%  50.0%  100.0% 
 
   % within 
Group  100.0% 
100.0
%  100.0% 
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HISTOLOGY FOR H.PYLORI 
 
 
 
Group  Total   
Control Study 
 
P 
value 
Histology 
for 
H.Plyori 
Positive  Count 
25  34  59 
 
      % within 
Histology 
for 
H.Plyori 
42.4%  57.6%  100.0% 
 
      % within 
Group  50.0%  68.0%  59.0% 
 
   Negative  Count  25  16  41   
      % within 
Histology 
for 
H.Plyori 
61.0%  39.0%  100.0% 
0.067 
      % within 
Group  50.0%  32.0%  41.0% 
 
Total  Count  50  50  100   
   % within 
Histology 
for 
H.Plyori 
50.0%  50.0%  100.0% 
 
   % within 
Group  100.0%  100.0% 100.0% 
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HISTOLOGY FOR H.PYLORI 
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RAPID UREASE TEST VS SEX CROSS TABULATION 
Sex  Group  Total   
Control  Study 
P 
value 
Male  Rapid 
Urease 
Positive  Count  18  25  43   
 
 
 
 
0.77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.224 
         % within 
Rapid 
Urease 
41.9%  58.1%  100.0% 
         % within 
Group  60.0%  80.6%  70.5% 
      Negative  Count  12  6  18 
         % within 
Rapid 
Urease 
66.7%  33.3%  100.0% 
         % within 
Group  40.0%  19.4%  29.5% 
   Total  Count  30  31  61 
   % within 
Rapid 
Urease 
49.2%  50.8%  100.0% 
   % within 
Group  100.0%  100.0%  100.0% 
Female  Rapid 
Urease 
Positive  Count  11  14  25 
         % within 
Rapid 
Urease 
44.0%  56.0%  100.0% 
         % within 
Group  55.0%  73.7%  64.1% 
      Negative  Count  9  5  14 
         % within 
Rapid 
Urease 
64.3%  35.7%  100.0% 
         % within 
Group  45.0%  26.3%  35.9% 
   Total  Count  20  19  39 
   % within 
Rapid 
Urease 
51.3%  48.7%  100.0% 
   % within 
Group  100.0%  100.0%  100.0% 
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RAPID UREASE TEST VS SEX CROSS TABULATION 
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RAPID UREASE VS HISTOLOGY FOR H.PYLORI 
Group       
Histology for 
H.Plyori  Total 
 
    Positive Negative  P value
 
Control 
Rapid 
Urease 
Positive Count 25  4  29    
 
 
 
 
 
<0.001**
(for both 
control 
and 
study 
groups) 
 
 
 
 
 
 
 
 
 
         % within 
Rapid 
Urease 
86.2%  13.8%  100.0% 
         % within 
Histology 
for H.Plyori 
100.0%  16.0%  58.0% 
      Negative Count 0 21 21 
         % within 
Rapid 
Urease 
.0%  100.0%  100.0% 
         % within 
Histology 
for H.Plyori 
.0%  84.0%  42.0% 
   Total  Count 25  25  50 
   % within 
Rapid 
Urease 
50.0%  50.0%  100.0% 
   % within 
Histology 
for H.Plyori 
100.0%  100.0%  100.0% 
Study  Rapid 
Urease 
Positive Count 34  5  39 
         % within 
Rapid 
Urease 
87.2%  12.8%  100.0% 
         % within 
Histology 
for H.Plyori 
100.0%  31.3%  78.0% 
      Negative Count 0 11 11 
         % within 
Rapid 
Urease 
.0%  100.0%  100.0% 
         % within 
Histology 
for H.Plyori 
.0%  68.8%  22.0% 
   Total  Count 34  16  50 
   % within 
Rapid 
Urease 
68.0%  32.0%  100.0% 
   % within 
Histology 
for H.Plyori 
100.0%  100.0%  100.0% 
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RAPID UREASE VS HISTOLOGY FOR H.PYLORI 
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RAPID UREASE VS PREMALIGNANT CHANGES 
Group        Atrophic Gastritis  Total   
      Positive  Negative    
P 
value 
Control  Rapid 
Urease 
Positive  Count  29  29   
         % within Rapid 
Urease  100.0%  100.0% 
         % within 
Atrophic 
Gastritis   
58.0%  58.0% 
      Negative Count  21  21 
         % within Rapid 
Urease  100.0%  100.0% 
         % within 
Atrophic 
Gastritis   
42.0%  42.0% 
   Total  Count  50  50 
   % within Rapid 
Urease  100.0%  100.0% 
   % within 
Atrophic 
Gastritis   
100.0%  100.0% 
Study  Rapid 
Urease 
Positive  Count  4  35  39 
         % within Rapid 
Urease  10.3%  89.7%  100.0% 
         % within 
Atrophic 
Gastritis 
100.0%  76.1%  78.0% 
 
0.268 
      Negative Count  0  11  11 
         % within Rapid 
Urease  .0%  100.0%  100.0% 
         % within 
Atrophic 
Gastritis 
.0%  23.9%  22.0% 
   Total  Count  4  46  50 
   % within Rapid 
Urease  8.0%  92.0%  100.0% 
   % within 
Atrophic 
Gastritis 
100.0%  100.0%  100.0% 
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RAPID UREASE VS PREMALIGNANT CHANGES 
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RAPID UREASE * ALCOHOL * GROUP 
Group  Alcohol  Total   
P valuePositive Negative
Control  Rapid 
Urease 
Positive  Count  16  13  29    
 
 
 
 
0.027* 
 
 
 
 
 
 
 
 
 
 
0.003**
         % within 
Rapid 
Urease 
55.2%  44.8%  100.0% 
         % within 
Alcohol  76.2%  44.8%  58.0% 
      Negative  Count  5  16  21 
         % within 
Rapid 
Urease 
23.8%  76.2%  100.0% 
         % within 
Alcohol  23.8%  55.2%  42.0% 
   Total  Count  21  29  50 
   % within 
Rapid 
Urease 
42.0%  58.0%  100.0% 
   % within 
Alcohol  100.0%  100.0%  100.0% 
Study  Rapid 
Urease 
Positive  Count  23  16  39 
         % within 
Rapid 
Urease 
59.0%  41.0%  100.0% 
         % within 
Alcohol  95.8%  61.5%  78.0% 
      Negative  Count  1  10  11 
         % within 
Rapid 
Urease 
9.1%  90.9%  100.0% 
         % within 
Alcohol  4.2%  38.5%  22.0% 
   Total  Count  24  26  50 
   % within 
Rapid 
Urease 
48.0%  52.0%  100.0% 
   % within 
Alcohol  100.0%  100.0%  100.0% 
 
 
47 
 
RAPID UREASE * ALCOHOL * GROUP 
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RAPID UREASE * SMOKER * GROUP 
Group        Smoker  Total   
P value       Positive  Negative    
Control  Rapid 
Urease 
Positive  Count  18  11  29   
 
 
 
 
0.007** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.240 
         % within 
Rapid 
Urease 
62.1%  37.9%  100.0% 
         % within 
Smoker  78.3%  40.7%  58.0% 
      Negative  Count  5  16  21 
         % within 
Rapid 
Urease 
23.8%  76.2%  100.0% 
         % within 
Smoker  21.7%  59.3%  42.0% 
   Total  Count  23  27  50 
   % within 
Rapid 
Urease 
46.0%  54.0%  100.0% 
   % within 
Smoker  100.0%  100.0%  100.0% 
Study  Rapid 
Urease 
Positive  Count  22  17  39 
         % within 
Rapid 
Urease 
56.4%  43.6%  100.0% 
         % within 
Smoker  84.6%  70.8%  78.0% 
      Negative Count  4  7  11 
         % within 
Rapid 
Urease 
36.4%  63.6%  100.0% 
         % within 
Smoker  15.4%  29.2%  22.0% 
   Total  Count  26  24  50 
   % within 
Rapid 
Urease 
52.0%  48.0%  100.0% 
   % within 
Smoker  100.0%  100.0%  100.0% 
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RAPID UREASE * SMOKER * GROUP 
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RAPID UREASE * TOBACCO * GROUP 
Group  Tobacco  Total   
P 
value Positive Negative
Control  Rapid 
Urease 
Positive  Count  14  15  29   
 
 
 
 
0.012* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.018*
         % within 
Rapid 
Urease 
48.3%  51.7%  100.0% 
         % within 
Tobacco  82.4%  45.5%  58.0% 
      Negative  Count  3  18  21 
         % within 
Rapid 
Urease 
14.3%  85.7%  100.0% 
         % within 
Tobacco  17.6%  54.5%  42.0% 
   Total  Count  17  33  50 
   % within 
Rapid 
Urease 
34.0%  66.0%  100.0% 
   % within 
Tobacco  100.0%  100.0%  100.0% 
Study  Rapid 
Urease 
Positive  Count  19  20  39 
         % within 
Rapid 
Urease 
48.7%  51.3%  100.0% 
         % within 
Tobacco  95.0%  66.7%  78.0% 
      Negative Count  1  10  11 
         % within 
Rapid 
Urease 
9.1%  90.9%  100.0% 
         % within 
Tobacco  5.0%  33.3%  22.0% 
   Total  Count  20  30  50 
   % within 
Rapid 
Urease 
40.0%  60.0%  100.0% 
   % within 
Tobacco  100.0%  100.0%  100.0% 
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RAPID UREASE * TOBACCO * GROUP 
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DISCUSSION 
The main risk factors for the development of gastric cancer are 
infection with Helicobacter pylori, dietary factors, cigarette smoking, 
obesity and an inherited predisposition. Considering that relatives of 
gastric carcinoma patients may be more prone to developing the disease 
themselves due to familial clustering, the presence of Helicobacter pylori 
in them may further increase the risk of their developing carcinoma 
stomach.  
Various studies have demonstrated that the first degree relatives of 
patients with gastric carcinoma are more likely to develop premalignant 
changes in the stomach and that these changes were mainly seen in 
persons with associated Helicobacter pylori infection. 
Previously conducted studies differ on the prevalence of H.pylori 
in the general population and first degree relatives of gastric carcinoma 
patients. Whereas some studies showed an increased prevalence of 
Helicobacter pylori in the latter group other studies couldn’t find any 
major difference between the prevalence in both the groups. 
Our study found that the prevalence of Helicobacter pylori 
infection was higher in the study group than that seen in the control 
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group. The prevalence of Helicobacter pylori was 58% in the control 
group, whereas it was 78% in the study group. This was found to be 
statistically significant with a p value of 0.032.  
Data obtained from South Korea indicates that persons with a 
family h/o gastric carcinoma have an increased incidence of not only 
Helicobacter pylori infection but are also associated with atrophic 
gastritis or intestinal metaplasia.(5) 185 patients with gastric carcinoma, 
130 of their siblings and 287 controls were recruited for this study. Status 
of Helicobacter pylori infection along with the histological changes was 
then assessed. Siblings were found to have a higher rate of infection with 
Helicobacter pylori (P = 0.046) and also a higher prevalence of intestinal 
metaplasia in the body of stomach (P = 0.027) when compared with the 
controls. They concluded that even in young adults, infection with 
Helicobacter pylori is to be considered a risk factor for gastric carcinoma 
and those with histopathological findings like corporal gastritis, corporal 
atrophy or intestinal metaplasia are at an increased risk. As siblings may 
share common risk factors, all family members should be advised 
screening. 
In our study, premalignant changes as evidenced by atrophic 
gastritis were present only in the study group. There were no such 
 
54 
 
changes seen in the control group. But this was statistically not significant 
(p=0.268) as the incidence of premalignant changes was very less. 
In a study conducted by Nasrin Zendehdel MD et al in Iran(6) 
between 2002 and 2005, 989 subjects who were first degree relatives of 
gastric carcinoma patients, aged between 40 and 65 years underwent 
upper GI scopies. After ruling out the presence of any gross lesions in the 
stomach, five tissue specimens were biopsied and then evaluated 
according to the Sydney Classification. One specimen was used for 
urease testing so as to determine the type and severity of the gastritis. 
They found that only 7% of stomach tissue specimens were normal. Two 
persons had gastric cancer and one had esophageal cancer. The rest of the 
persons had premalignant changes with predominant atrophic gastritis 
and few cases with intestinal dysplasia. They concluded that about one-
fifth of the first degree relatives had H.pylori induced corpus-
predominant gastritis and that since these people are at increased risk for 
developing carcinoma stomach, H.pylori eradication is indicated.  
In a study by Whiting JL et al in patients with atrophic gastritis or 
intestinal metaplasia, an 11% increased risk of developing gastric 
carcinoma was reported  when followed up for a period of 10 years.(7) 
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  In our study, what stood out was the fact that all the 4 persons 
(100%) who showed atrophic gastritis had evidence of Helicobacter 
pylori infection (as confirmed by a positive rapid urease test). 
In our study, there was a slight discordance between the rapid 
urease test and the histological evidence of Helicobacter pylori in both 
groups. Only 25 out of the 29 persons in the control group and 34 out of 
39 persons in the study group with a positive rapid urease test were able 
to demonstrate histological evidence of H.pylori. This discordance may 
be due to the fact that only eosin and hemotoxylin stains were used in the 
histological examination. Application of special stains such as Modified 
Giemsa, Silver stains etc., may have aided in accurately detecting 
Helicobacter pylori. Hence, we may infer that the rapid urease test may 
be more sensitive for the identification of Helicobacter pylori infection 
and can be used in the endoscopy suite itself to diagnose and treat 
Helicobacter pylori. 
All persons in our study with a positive rapid urease test were 
treated as a case of Helicobacter pylori infection and were put on triple 
therapy with two antibiotics (amoxicillin and clarithromycin) and a PPI.  
Wong et al were the first to conduct and publish a prospective RCT 
that looked into the effect of eradication of Helicobacter pylori on the 
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development of gastric carcinoma in 2004.(8) They randomized 1630 
persons from a high-risk region in China with confirmed H. pylori 
infection to either receive eradication therapy or placebo.  Following 
these persons for 7.5 years, there was no significant difference in the 
development of gastric carcinoma between the two groups (7 vs11 cases, 
P= 0.33). But, a detailed subgroup analysis demonstrated a significant 
benefit (P = 0.02) from eradication of H.pylori in persons who didn’t 
have intestinal metaplasia at the time of enrollment in this study. 
There are no clear guidelines regarding surveillance in cases with 
premalignant changes in the stomach. 
ASGE guidelines 
The ASGE guidelines for gastric intestinal metaplasia are: 
• Endoscopic surveillance for gastric intestinal metaplasia can’t be 
uniformly recommended as this entity hasn’t been studied 
extensively in the USA. 
• Patients who have an increased risk for gastric carcinoma due to 
ethnic background or family history may benefit from surveillance. 
• Endoscopic surveillance should incorporate topographic mapping 
of the entire stomach. 
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Unfortunately, there are no randomized studies comparing different 
strategies in this situation, with endoscopic control performed yearly, 
every 2 years or less frequently in various centers. But, in a UK study 
with a yearly endoscopic control, 36% of detected gastric cancers were 
stage I disease, a rate which would appear similar to the 38% achieved in 
Italy with a 2-year endoscopic control.(9) 
The Annual Symposium of the Korean College of Helicobacter and 
Upper Gastrointestinal Research asked its members to discuss, vote and 
recommend screening strategies for premalignant changes in stomach. 
These recommendations were published in the March 2012 issue of the 
Digestive Diseases & Sciences Vol. 57 Issue 3, p746. The commonly 
recommended suggestion for persons with intestinal metaplasia was to 
have an annual endoscopic follow-up (95.5% vs. 80.4% in the expert and 
non-expert groups, respectively; P = 0.118). The same follow-up was also 
recommended for those with atrophic gastritis (95.5% vs. 76.5%; P = 
0.092). This was irrespective of the physicians' endoscopic experience, 
position and type of the hospital. 
In another study by Angelo Zullo et al published in World J 
Gastrointest Oncol. 2012 March 15; 4(3): 30–36, reported that H. pylori 
eradication may slow intestinal metaplasia progression, scheduled 
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endoscopic control could be cost-effective in intestinal metaplasia 
patients and  that yearly and 2 yearly controls seem to be equally 
effective but specific studies are needed in this setting. 
The persons in the study group with atrophic gastritis were advised 
to have an annual surveillance upper GI scopy. This was advised to 
monitor the patient and detect gastric carcinoma (if it occurs) at an early 
stage as there is a better 5 year survival rate when the disease is identified 
earlier on. 
However, larger multicenter randomized control trials across 
countries are needed to find out the potential benefits of such a 
surveillance programme and whether their application will vary in 
regions with low incidence from those that have a high incidence of 
gastric cancer. 
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CONCLUSION 
 This study shows that the prevalence of Helicobacter pylori is 
higher in first degree relatives of patients with gastric carcinoma 
than that seen in the control group. 
 The presence of premalignant changes (atrophic gastritis) was 
seen only in a few persons in the the study group.  
 Premalignant changes were seen only in persons who showed the 
presence of Helicobacter pylori as evidenced by the presence of a 
positive rapid urease test and positive histological examination. 
 Rapid urease test was slightly more sensitive than histological 
examination in the detection of H.pylori. 
 This study showed a positive correlation between alcohol intake 
and tobacco chewing with the prevalence of H.pylori, whereas 
there was an inconsistent correlation between smoking and 
H.pylori. 
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PROFORMA 
NAME: 
AGE:                       SEX:                            OCCUPATION:                       
SOCIO-ECONOMIC STATUS: 
ADDRESS: 
DDHD NUMBER: 
PRESENTING COMPLAINTS: 
RELEVANT HISTORY: 
HISTORY OF PUD:                                                                               
HISTORY OF GASTRECTOMY: 
HISTORY OF ALCOHOLISM: 
HISTORY OF SMOKING/ TOBACCO/SNUFF: 
HISTORY OF EXPOSURE TO STD:    
HISTORY OF OTHER COMORBID CONDITIONS: 
GENERAL EXAMINATION:    
PALLOR:   , ICTERUS:   ,CLUBBING:   , CYANOSIS:   ,PEDAL 
EDEMA:   , LYMPHADENOPATHY(GENERAL AND LT. 
SUBCLAVIAN) :  
HEIGHT:                       WEIGHT:                                    BMI: 
JVP:                       TEMPERATURE:                                PULSE:                                   
BLOOD PRESSURE: 
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EXAMINATION OF THE ABDOMEN: 
 MASS ABDOMEN: 
 HEPATOMEGALY: 
ASCITES:                                                                     VGP:                   
SUCCUSSION SPLASH: 
PER RECTAL EXAM: 
EXAMINATION OF THE CARDIOVASCULAR SYSTEM:  
EXAMINATION OF THE RESPIRATORY SYSTEM: 
EXAMINATION OF THE NERVOUS SYSTEM: 
DIAGNOSIS: 
                                                                                                                                             
INVESTIGATIONS 
COMPLETE HEMOGRAM: 
HEMOGLOBIN:        TOTAL COUNT:                       DIFFERENTIAL 
COUNT: P    L    B    E    M   
 PLATELET COUNT:                                         ESR:    
BLOOD SUGAR:              BLOOD UREA:                 SERUM 
CREATININE: 
STOOL OCCULT BLOOD:                                             XRAY CHEST: 
ULTRASONOGRAPHY ABDOMEN: 
OGD SCOPY FINDINGS: 
 
RAPID UREASE TEST: 
HISTOPATHOLOGICAL EXAMINATION FINDINGS: 
  
 
70 
 
 
 
 
 
 
 
MASTER CHART 
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STUDY GROUP 
Sl.No NAME 
DDHD  
NUMBER AGE SEX SMOKER ALCOHOL TOBACCO RAPID 
HISTOLOGY 
FOR ATROPHIC INTESTINAL DYSPLASIA 
                UREASE H.PYLORI GASTRITIS 
     
METAPLASIA   
1 GIRIJA 6381/12 48 F N N N N N N N N 
2 MAHALAKSHMI 6630/12 20 F N N N P N N N N 
3 MUTHURAMAN 7304/12 40 M P P P N N N N N 
4 THAMARAISELVAN 7305/12 35 M P P N P P N N N 
5 SELVI 7670/12 23 F N N N P P N N N 
6 THANGAMALAR 5034/12 35 F N N P P P N N N 
7 DHARMALINGAM 1265/12 33 M P P P P P N N N 
8 PARTHIBAN 8000/12 22 M N P N P P N N N 
9 ISAKKIPANDIAN 758/13 34 M P P P P P N N N 
10 DHANASEKHAR 7169/12 43 M P N N N N N N N 
11 MUNUSAMY 7790/12 30 M P P N P P N N N 
12 NOOR JAHAN 7296/12 48 F N N P P N N N N 
13 MOHD.ISMAIL 7599/12 19 M N N N P P N N N 
14 GEETHA 6323/12 42 F N N P P P P N N 
15 MEENAVATHY 7081/12 45 F N N N P P N N N 
16 VISWANATHAN 5911/12 56 M P P P P P P N N 
17 VIJAYA 6774/12 50 F N N P P P N N N 
18 YUVARAJ 6658/12 35 M P P P P P N N N 
19 MOHAN 7184/12 28 M P P N P N N N N 
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20 GOVINDAN 7798/12 48 M P N N N N N N N 
21 KRISHNAN 5911/12 56 M N P P P P P N N 
22 PALANISAMY 3414/08 29 M P P N P P N N N 
23 VEDAGIRI 4110/12 55 M P P P P P N N N 
24 NITHYA 7736/12 14 F N N N N N N N N 
25 VELU 3414/08 29 M P P N P P N N N 
26 BALAKRISHNAN 7742/12 35 M P P P P P N N N 
27 JEYASHREE 5988/12 28 F N N N N N N N N 
28 PANEERSELVAM 7834/12 25 M P P N P P N N N 
29 JEYASUDHA 1177/09 26 F N N N P P N N N 
30 NAGARAJAN 7902/12 42 M P P P P P P N N 
31 VENKATESAN 5623/09 35 M P P N P P N N N 
32 PUSHPA 1314/13 34 F N N N N N N N N 
33 SRIRAM 7883/12 40 M P P P P P N N N 
34 NETHAJI 8071/12 60 M N N N N N N N N 
35 LAKSHMI 7510/12 33 F N N N P P N N N 
36 VISALAKSHI 184/13 25 F N N N P P N N N 
37 SHANKAR 33/13 39 M P P N P N N N N 
38 PETCHIAMMAL 8200/12 33 F N N P P P N N N 
39 CHINNA REDDY 349/13 41 M P P P P P N N N 
40 VEERA PRASANNA 1460/13 25 M P P N P P N N N 
41 RAMACHANDRA 6465/12 18 M N N N N N N N N 
42 SELVAM 7685/12 37 M P P P P P N N N 
43 RANI 5277/12 35 F N N P P P N N N 
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44 NATARAJAN 3310/12 34 M P P P P P N N N 
45 SHANKAR 79/13 38 M P N N N N N N N 
46 PETCHIAMMAL 8178/12 32 F N N N P P N N N 
47 SUMATHI 298/13 44 F N N P P P N N N 
48 LAKSHMI 267/13 55 F N N N N N N N N 
49 KESAVAN 1685/12 31 M P P N P P N N N 
50 CHAKRAVARTHI 661/13 25 M P N N P N N N N 
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Control Group 
1 ISAAC 7379/12 29 M P P P P P N N N
2 RAJESWARI 7655/12 46 F N N P P P N N N 
3 KOKILA 5790/12 36 F N N N N N N N N 
4 RAJKUMAR 7710/12 19 M N P N N N N N N 
5 SUNDAR 225/11 53 M P P P P P N N N 
6 ARASU 7814/12 31 M P N N N N N N N 
7 DAMAYANTHI 5514/12 33 F N N N N N N N N
8 MARY 7873/12 46 F N N P P P N N N 
9 RAJU 7969/12 27 M P P N P P N N N 
10 MURUGAN 7966/12 21 M P P N P N N N N 
11 THIRAVIDAMANI 7917/12 30 M P N N N N N N N 
12 VASUKI 8077/12 40 F N N N P P N N N 
13 RAMESH 4210/12 33 M P P N P P N N N 
14 ARULPRAKASAM 8074/12 30 M P P N P P N N N 
15 MOORTHY 8106/12 30 M N N P N N N N N 
16 SHANTHI 8127/12 45 F N N P P P N N N
17 VINOTH 8021/12 23 M N N N N N N N N 
18 KARPAGAM 8072/12 32 F N N N N N N N N 
19 LAKSHMI 48/13 37 F N N N N N N N N 
20 JAYAKUMAR 5717/11 43 M P P N P P N N N 
21 AMUDHAVALLI 8011/11 30 F N N N N N N N N 
22 UMAPATHY 121/13 35 M P P N P P N N N
23 LAKSHMI 148/13 47 F N N P P P N N N 
24 MUNIAPPAN 176/13 23 M N P N N N N N N 
25 JEYARAMAN 193/13 53 M P P P P P N N N 
26 NEELAM DEVI 7928/12 35 F N N N P P N N N 
27 RAVI 3132/12 45 M P P N P P N N N 
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28 VASANTHA 329/13 56 F N N P P P N N N 
29 KAMARAJ 335/13 41 M P P N P P N N N 
30 JEYARAJAN 4748/10 40 M P P P P P N N N 
31 GOVINDASAMY 458/13 28 M P P N P N N N N
32 RAJAN 460/13 37 M P P P P P N N N 
33 ROBERT 443/13 35 M P P N N N N N N 
34 KALYANI 450/13 52 F N N P P P N N N 
35 KASTHURI 563/13 45 F N N N N N N N N 
36 MOHANRAJ 482/13 42 M P N N P P N N N 
37 SELVI 597/13 27 F N N N N N N N N 
38 ROHINI 6125/04 38 F N N N P N N N N 
39 KUMAR 552/13 34 M N P N N N N N N 
40 BAKRUDEEN 6540/09 50 M P P P P P N N N 
41 RUKMANI 403/13 65 F N N P P P N N N 
42 LAKSHMI 4354/11 15 F N N N N N N N N 
43 RAJINI 5261/12 26 M P N N N N N N N 
44 KARUNANIDHI 775/13 21 M N P P N N N N N 
45 UMA 712/13 30 F N N N N N N N N 
46 SUNDARAM 809/13 48 M P P N P P N N N
47 GOKUL 813/13 16 M P N N N N N N N 
48 BHARATHY 915/13 53 F N N P P P N N N 
49 RAMESH 779/13 30 M P N N P N N N N 
50 SELVAKUMAR 908/13 26 M N N P N N N N N 
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